Correspondence

Dengue Vascular Permeability Syndrome: What, No T Cells?

TO THE EDITOR—Tam et al found that 0.5 or 2.0 mg/kg of prednisolone administered orally for 3 consecutive days early in the course of dengue disease in Vietnamese children or adults failed to reduce subsequent abnormal hemostasis or loss of fluid from capillaries [1]. This result was greeted with dismay because an anticipated accessible and inexpensive ameliorative treatment of the dengue vascular permeability syndrome had failed, but neither the authors nor a published commentary identified the full significance of this audacious clinical trial [2].

The unusual clinical course of severe dengue permits early access to patients as illness begins with the sudden-onset fever that prompts many patients to seek medical attention. However, the abnormal hemostasis and increased vascular permeability that comprise the dengue vascular permeability syndrome occur several days after onset of fever, usually during defervescence. Thus, during dengue illnesses there is a therapeutic window for possible early intervention. The short duration of dengue vascular permeability has led most investigators to entertain the hypothesis of an underlying pharmacological mechanism, with central efforts focused on cytokines released during the elimination of dengue-infected cells [3].

As evidence of some therapeutic effect, in the Vietnam trial prednisolone slightly reversed leukopenia and aspartate aminotransferase levels, but the full immune elimination event was not altered as all patients recovered from their dengue infection uneventfully and on schedule. The steroid doses administered should have been immunosuppressive, so perhaps the dengue vascular permeability syndrome is not T cell mediated. If not, what could be the late-in-illness pathogenic mechanism? The answer may reside in an old suspect—the dengue-soluble complement-fixing antigen, or nonstructural protein 1 (NS1) [4]. Recently, Lin et al have found that during the late stages of dengue disease NS1 circulates as complexes with thrombin [5]. More importantly, NS1 also forms complexes with prothrombin, resulting in a prolongation of activated partial thromboplastin times, values that have been shown to be the strongest correlate of vascular permeability in patients with dengue infection [6]. As its original name implies, NS1 interacts powerfully with the complement system, and complement activation once was recognized as an intrinsic component of the dengue vascular permeability syndrome [7, 8]. Might the release of NS1 from dengue-infected cells contribute to the late onset of the dengue shock syndrome? Studies on the virological course of dengue infections in monkeys found that peak cellular infection occurred at the end of the viremic phase [9]. If this is true for humans, then during defervescence the cell elimination immune process may release a bolus of NS1, which—still biologically active despite circulating as immune complexes—produces a NS1 toxicosis. It is well to recall that NS1 vaccines have shown protection against flavivirus disease [10]. The results of the Vietnam study surely demand a major new thrust to dengue pathogenesis research.

Note

Potential conflicts of interest. The author certifies no potential conflicts of interest.

The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Scott B. Halstead
Dengue Vaccine Initiative, International Vaccine Institute, Seoul, Korea

References

10. Schlesinger JJ, Brandriss MW, Cropp CB, Monath TP. Protection against yellow fever in monkeys by immunization with yellow...

Correspondence: Scott B. Halstead, 5824 Edson Lane, North Bethesda, MD 20852 (halsteads@erols.com).

Clinical Infectious Diseases 2013;56(6):900–1
© The Author 2012. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
DOI: 10.1093/cid/cis1047